Systemic treatment of non-small-cell lung cancer

European Journal of Cancer

Volumn 47, Issue SUPPL. 3, 2011, Pages

  Lal, Rohit ^a   Enting, Deborah ^a   Kristeleit, Hartmut ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; NEOPLASM STAGING; PREOPERATIVE PERIOD; RADIOTHERAPY, ADJUVANT;

EID: 80053240056     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/S0959-8049(11)70209-X     Document Type: Article

References (24)

1. SS Burdett, LA Stewart, L Rydzewska Chemotherapy and surgery versus surgery alone in non-small cell lung cancer Cochrane Database Syst Rev 3 2007 CD006157
2. D Gilligan, M Nicolson, I Smith et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review Lancet 369 9577 2007 1929 1937 (Pubitemid 46874559)
3. L Crino, W Weder, J Van Meerbeeck, E Felip, on behalf of the ESMO Guidelines Working Group Ann Oncol 21 Suppl 5 2010 vl03 vl15
4. KMW Pisters, WK Evans, CG Azzoli et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guidelines J Clin Oncol 25 2007 5506 5518 (Pubitemid 350232227)
5. J-P Pignon, H Tribodet, GV Scagliotti et al. Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group J Clin Oncol 26 2008 3552 3559
6. R Amagada, B Bergman, A Dunant et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N EnglJ Med 350 4 2004 351 360 (Pubitemid 38101630)
7. JY Douillard, R Rosell, M De Lena et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 9 2006 719 727 (Pubitemid 44283661)
8. C Pepe, B Hasan, TL Winton et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR. 10 J Clin Oncol 25 12 2007 1553 1561 (Pubitemid 46733082)
9. KA Olaussen, A Dunant, P Fouret et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N EnglJ Med 355 2006 983 991 (Pubitemid 44343542)
10. A Aupérin, C Le Péchoux, JP Pignon et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 3 2006 473 483 (Pubitemid 43329586)
11. JP van Meerbeeck, GW Kramer, PE Van Schil et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer JNatl Cancer Inst 99 6 2007 442 450 (Pubitemid 47073567)
12. TS Mok, Y-L Wu, S Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
13. R Pirker, JR Pereira, A Szczesna et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 9674 2009 May 2 1525 1531
14. A Sandier, R Gray, MC Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
15. SS Ramalingam, SE Dahlberg, CJ Langer et al. Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599 J Clin Oncol 26 2008 60 65
16. GV Scagliotti, F De Marinis, M Rinaldi Italian Lung Cancer Project Phase III randomized trial comparing three-platinum-based doublets in advanced non-small-cell lung cancer JClin Oncol 20 2002 4285 4291 (Pubitemid 35266288)
17. G Scagliotti, N Hanna, F Fossella et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 2009 253 263
18. K Kelly, K Chansky, LE Gaspar et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
19. T Ciuleanu, T Brodowicz, C Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
20. F Cappuzzo, T Ciuleanu, L Stelmakh et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet 11 2010 521 529
21. N Hanna, FA Shephard, FV Fossella et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597 (Pubitemid 41079796)
22. T Winton, R Livingston, D Johnson et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer NEnglJMed 352 2005 2589 2597 (Pubitemid 41007845)
23. W Pao, TY Wang, GJ Riely et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 el7
24. DA Eberhard, BE Johnson, LC Amler et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909